Short‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D : A : D study
Year: 2015
Type: article
Abstract: OBJECTIVES: The aim of the study was to assess the impact of the gain in body mass index (BMI) observed immediately after antiretroviral therapy (ART) initiation on the subsequent risk of cardiovascular disease (CVD) and diabetes. METHODS: We analysed data from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort study. Outcomes were development of (i) CVD (composite of myocardial infarction/stroke/coronary procedure) and (ii) diabetes. The main exposure variable was change in BMI from ART initiation (pre-ART) to 1 year after initiation (continuous variable) in treatment-naïve individuals initiating ART with no history of CVD or diabetes (for respective outcomes). BMI [weight (kg)/(height (m))(2)] was categorized as underweight (< 18.5), normal (18.5-25), overweight (25-30) and obese (> 30). Poisson regression models were fitted stratified for each pre-ART BMI category to allow for category-specific estimates of incidence rate ratio (IRR). Models were adjusted for pre-ART BMI and CD4 count, key known risk factors (time-updated where possible) and calendar year. RESULTS: A total of 97 CVD events occurred in 43,982 person-years (n = 9321) and 125 diabetes events in 43,278 person-years (n = 9193). In fully adjusted analyses for CVD, the IRR/unit gain in BMI (95% confidence interval) in the first year of ART, by pre-ART BMI category, was: underweight, 0.90 (0.60-1.37); normal, 1.18 (1.05-1.33); overweight, 0.87 (0.70-1.10), and obese, 0.95 (0.71-1.28) (P for interaction = 0.04). For diabetes, the IRR/unit gain in BMI was 1.11 (95% confidence interval 1.03 to 1.21), regardless of pre-ART BMI (P for interaction > 0.05). CONCLUSIONS: Short-term gain in BMI following ART initiation appeared to increase the longer term risk of CVD, but only in those with pre-ART BMI in the normal range. It was also associated with increased risk of diabetes regardless of pre-ART BMI.
Source: HIV Medicine
DOI: 10.1111/hiv.12294
Authors: AC Achhra, A Mocroft, P Reiss, C Sabin, L Ryom, S de Wit, CJ Smith, A d'Arminio Monforte, A Phillips, R Weber, J Lundgren, MG Law, the D:A:D Study Group
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: National Science Foundation, Boehringer Ingelheim, Bristol-Myers Squibb Foundation, amfAR, The Foundation for AIDS Research, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Roche, Styrelsen för Internationellt Utvecklingssamarbete, Gilead Sciences, AbbVie, ViiV Healthcare, Australian Government, European Commission, Department of Health and Ageing, Australian Government, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, University of New South Wales, Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Fundación Para La Innovación Y La Prospectiva En Salud En España, National Institutes of Health, U.S. Food and Drug Administration, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Janssen Pharmaceuticals
Awards: The role of APOL1 polymorphisms in promoting HIV-related kidney injury, G2481942132, G3420673185, COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDS, G4341623618, Swiss HIV Cohort Study (SHCS), TERRY BEIRN COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON, G5989766014, G6177813060, IeDEA Asia-Pacific Research Collaboration
OpenAlex ID: W1535373147
